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Clinical Investigation
Right Heart Dysfunction in Heart Failure With Preserved
Ejection Fraction: The Impact of Atrial Fibrillation
THOMAS M. GORTER, MD,1 JOOST P. VAN MELLE, MD, PhD,1 MICHIEL RIENSTRA, MD, PhD,1 BARRY A. BORLAUG, MD,2
YORAN M. HUMMEL, PhD,1 ISABELLE C. VAN GELDER, MD PhD,1 ELKE S. HOENDERMIS, MD, PhD,1
ADRIAAN A. VOORS, MD, PhD,1 DIRK J. VAN VELDHUISEN, MD PhD,1 AND CAROLYN S.P. LAM, MD, PhD1,3
Groningen, The Netherlands; Rochester, Minnesota; and Singapore
ABSTRACT
Background: Right ventricular (RV) dysfunction and atrial fibrillation (AF) frequently coexist in heart failure
with preserved ejection fraction (HFpEF). The mechanisms underlying the association between AF and RV
dysfunction are incompletely understood.
Methods and Results: We identified 102 patients. RV function was assessed with the use of multiple
echocardiographic parameters, and dysfunction was present if ≥2 parameters were below the recom-
mended cutoffs. RV function, right atrial (RA) reservoir strain, and RA emptying fraction were compared
between AF and sinus rhythm. We included 91 patients with sufficient echocardiographic quality: 45 (50%)
had no history of AF, 14 (15%) had earlier AF while in sinus rhythm, and 32 (35%) had current AF. The
prevalence of RV dysfunction varied across subgroups (never AF, earlier AF, and current AF: 20%, 43%
and 63%, respectively; P = .001). AF was associated with RV dysfunction (odds ratio [OR] 4.70 [95% con-
fidence interval [CI] 1.82–12.1]; P = .001) independently from pulmonary pressures. In patients in sinus
rhythm with earlier AF, RA emptying fraction was lower compared with patients without AF history (41
vs 60%; P = .002). Earlier AF was also associated with reduced RA reservoir strain (OR 4.57 [95% CI 1.05–
19.9]; P = .04) independently from RV end-diastolic pressure.
Conclusions: Atrial fibrillation is strongly related to reduced RV and RA function in HFpEF indepen-
dently from pulmonary pressures. (J Cardiac Fail 2018;24:177–185)
Key Words: HFpEF, Right ventricular dysfunction, Atrial fibrillation.
Right ventricular (RV) dysfunction and atrial fibrillation
(AF) are common in patients with heart failure with pre-
served ejection fraction (HFpEF); they often coexist and are
independently associated with a poor prognosis.1–3 Recent
studies have indicated a potential relationship between AF
and RV dysfunction in HFpEF.4–9 For example, the preva-
lence of AF in patients without RV dysfunction ranges from
31% to 53%, compared with 65%–73% prevalence of AF in
HFpEF patients with RV dysfunction.4,5,7 Although these pa-
tients with RV dysfunction also had higher pulmonary
pressures, the association between AF and RV dysfunction
in HFpEF appeared to be unrelated to pulmonary pressures.4,9
Whether these patients with higher prevalence of both RV dys-
function and AF represent the “sicker” HFpEF patient is
unknown. Possible load-independent factors associated with
RV dysfunction in the setting of AF in HFpEF are incom-
pletely understood, and studies with the primary aim to
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investigate these associations have not been carried out. Fur-
thermore, although left atrial (LA) remodeling in patients with
HFpEF and AF is extensively investigated,10 the association
with right atrial (RA) remodeling has so far not been studied
and compared to simultaneous criterion-gold standard inva-
sive hemodynamics in HFpEF-AF. We therefore aimed in the
present study to compare RV and RA function in AF versus
sinus rhythm among patients with HFpEF undergoing simul-
taneous right heart catheterization and echocardiography. We
hypothesized that RA function is simultaneously impaired in
HFpEF-AF and further contributes to RV dysfunction, inde-
pendently from RV afterload.
Methods
The study population of this observational cohort study
was recently described8 and consisted of 102 symptomatic
HFpEF patients with New York Heart Association (NYHA)
functional class ≥II and left ventricular ejection fraction
(LVEF) ≥45%, who had echocardiographic signs of el-
evated right-side pressures and therefore underwent routine
left- and right-side heart catheterization for the evaluation
of pulmonary hypertension. Patients without a simultane-
ous echocardiographic assessment were excluded. Patients
were also excluded if RV systolic function could not be
measured reliably with the use of ≥2 recommended
echocardiographic indices for RV systolic function (see
further details below).
Baseline demographic and clinical characteristics, as well
as heart rate during the assessment and atrial fibrillation/
flutter history, were obtained. Patients also underwent a
physical examination and a laboratory test, including
N-terminal pro–B-type natriuretic peptide (NT-proBNP). Pa-
tients were divided into 3 subgroups: patients in sinus rhythm
and without a history of AF (never AF), patients in sinus
rhythm during the assessment but with an earlier diagnosis
of AF (earlier AF) and patients who were in AF during the
assessment (current AF).
Right Heart Catheterization Protocol
All patients underwent a right heart catheterization in fasting
state and in supine position as previously described in detail.11
The right heart catheterization was performed by a single ex-
perienced interventional cardiologist (ESH). A 7-F
thermodilution balloon-tipped catheter was inserted through
the femoral vein and advanced into the right atrium and right
ventricle. The catheter was subsequently positioned in the pul-
monary artery and wedge position. RA pressure, RV end-
diastolic pressure (RVEDP), pulmonary artery pressure (PAP),
and pulmonary capillary wedge pressure (PCWP) were ob-
tained at end-expiration, Arteriovenous oxygen difference (A-
VO2 diff) was determined as the difference between directly
measured arterial and mixed venous O2 contents from blood
sampling. Cardiac output (CO) was calculated by means of
the Fick equation with the use of estimated O2 consumption
(CO = VO2/A-VO2 diff) and indexed for body surface area
to calculate cardiac index (CI). Pulmonary vascular resis-
tance (PVR) was calculated as mean (PAP − PCWP)/CO.
Echocardiographic Protocol
Echocardiographic images were acquired simultaneously
with the right heart catheterization by a single experienced
ultrasound technician (YMH) with the use of a Vivid S6 system
(General Electric, Horton, Norway) with a 2.5- to 3.5-MHz
probe. Images were digitally stored for offline analyses. Anal-
yses were independently performed by 2 experienced
investigators (TMG and YMH) with the use of GE EchoPAC
version BT12. All measurements were performed in dupli-
cate on 2 time points, and the average values were calculated.
For patients in AF, measurements were averaged from the
available heart beats (3–4 cycles).
RV-focused apical 4-chamber views were obtained and RV
dysfunction assessed by means of tricuspid annular plane sys-
tolic excursion (TAPSE), systolic annular tissue velocity of the
lateral tricuspid annulus (RVS′), RVfractional area change (FAC),
and RV free wall longitudinal strain (FWLS) according to pre-
vious recommendations.12 RVdysfunction was considered present
if ≥2 of the measures of RV function were below the lower limit
of normal (ie, TAPSE <17 mm, RV S′ <9.5 cm/s, RV FAC <35%,
and RV FWLS >−20%).12 Right ventricular myocardial per-
formance index (RV Tei-index) was calculated by means of the
tissue Doppler method (ie, isovolumetric time − isovolumetric
relaxation time, divided by total RV ejection time), where larger
values indicate poorer RV myocardial performance.12 Right
ventricular–vascular coupling was assessed by calculating the
ratio of TAPSE to simultaneously derived invasive systolic PAP
(ie, TAPSE/SPAP).13
Furthermore, RA maximum (end-systolic) and minimum
(end-diastolic) volumes were calculated by summation of the
discs in the apical 4-chamber view. Total RA emptying frac-
tion was calculated as maximum volume − minimum volume,
divided by maximum volume (Fig. 1A). With the use of
2-dimensional echocardiographic speckle tracking, RA en-
docardial contours were traced and RA reservoir strain
subsequently measured (Fig. 1B). There are no established
cutoff values for reduced RA emptying fraction and RA res-
ervoir strain. Therefore, RA emptying fraction and reservoir
strain were dichotomized on the basis of the median value,
and reduced emptying fraction and reservoir strain were
defined as the group below the median.
In addition, RA compliance was calculated as follows: RA
stroke volume (ie, maximum − minimum volume) divided by
RA pulse pressure (RA maximum − minimum pressure), ob-
tained from the invasive RA pressure waves.14 RA compliance
was expressed as mL/mm Hg.
Statistical Analyses
Data are summarized as mean ± SD, median (interquartile
range [IQR]) or n (%). analysis of variance was used to test
between-group equality of the means of continuous
variables. The Welch F test was used when the assumption
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of homogeneity of variances was violated. In addition, mul-
tiple comparisons between subgroups were performed with
Bonferroni correction. Chi-square tests and Fisher exact tests
were used to test for differences in distributions of cat-
egoric variables. Associations with the presence of RV and
RA dysfunction were conducted with the use of binary lo-
gistic regression. Unadjusted and adjusted odds ratios (ORs)
with their 95% confidence intervals (CIs) were estimated. For
continuous variables, ORs are presented per SD change to
facilitate comparisons between ORs for different variables.
The minimum number of events per adjustment variable in
the logistic regression analysis was set at 10, based on pre-
vious recommendations.15,16 Statistical significance was
considered to be achieved with P value <.05. All statistical
analyses were performed with the use of SPSS (version 22,
2013).
Results
Four patients were excluded from the identified study
sample because they did not undergo simultaneous
echocardiography. In 7 patients, RV systolic function could
not be assessed reliably with ≥2 echocardiographic param-
eters, and those patients were excluded as well. Thus in total,
91 HFpEF patients were included in the present study.
Of these, 45 patients (49.5%) had no history of AF, 14
(15.4%) had earlier AF and were currently in sinus rhythm,
Fig. 1. Echocardiographic methods for the assessment of right atrial (RA) function. (A) Assessment of RA emptying fraction (RAEF) with
the use of the area-length method in the apical 4-chamber view, and (B) assessment of RA reservoir strain with the use of echocardiographic
2-dimensional speckle tracking strain.
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and 32 (35.2%) were currently in AF. Of the 14 patients with
earlier AF, 7 (7.7%) had paroxysmal AF, 5 (5.5%) persis-
tent AF, and 2 (2.2%) atrial flutter.
Patients with current AF had a median duration from 1st
diagnosis of 7.5 (IQR 3.2–11.1) years, and for patients with
earlier AF this interval from 1st diagnosis to baseline assess-
ment was 2.0 (IQR 0.6–4.0) years. Table 1 summarizes the
baseline characteristics of the study population according to
the 3 subgroups. Patients in AF were more symptomatic and
had higher PCWP and PAP than patients who were in sinus
rhythm.
Right Ventricular Function in Atrial Fibrillation Versus
Sinus Rhythm
A total of 35 patients (38.5%) had RV dysfunction. As pre-
sented in Table 1, the prevalence of RV dysfunction varied
significantly across the 3 subgroups (never AF, earlier AF,
and current AF: 20%, 43%, and 63%, respectively;
P = .001).
Figure 2 illustrates the association between AF and
echocardiographic parameters that reflect RV function. All
measures of RV function were significantly lower in pa-
tients with current AF compared with patients without any
history of AF. Patients with current AF also had higher RV
Tei-index and lower TAPSE/SPAP ratio. Furthermore, there
was a significant difference observed for all RV parameters
across the 3 subgroups, but there were no statistical signif-
icant differences in RV parameters between the 2 subgroups
in sinus rhythm (ie, never AF vs earlier AF).
Table 2 details the logistic regression model for the asso-
ciation with RV dysfunction in HFpEF. AF, male sex,
permanent pacing, and reduced LVEF remained associated
with RV dysfunction after adjustment for mean PAP.







(n = 32) P Value
Age (y) 73 ± 8 76 ± 5 75 ± 11 .49
Male sex 11 (24%) 7 (50%) 10 (31%) .19
Body mass index (kg/m2) 28.3 ± 5.6 26.2 ± 2.8 29.1 ± 6.7 .33
New York Heart Association functional class II/III 58% / 42% 43% / 57% 19% / 81%* .003‡
Hypertension 31 (69%) 9 (64%) 20 (63%) .84
Coronary artery disease 15 (33%) 6 (43%) 11 (34%) .80
Pacemaker 3 (7%) 4 (29%) 5 (16%) .09
Chronic obstructive pulmonary disease 8 (18%) 1 (7%) 5 (16%) .63
Right heart catheterization
Heart rate (beats/min) 71 ± 11 68 ± 11 74 ± 15 .35
LV end-diastolic pressure (mm Hg) 17 ± 7 16 ± 6 18 ± 3 .75
Pulmonary capillary wedge pressure (mm Hg) 16 ± 7 17 ± 6 20 ± 4* .01‡
Mean pulmonary artery pressure (mm Hg) 29 ± 10 29 ± 11 34 ± 7* .03‡
RV end-diastolic pressure (mm Hg) 8 ± 4.0 8 ± 4.0 11 ± 4.0 * .008*
Mean right atrial pressure (mm Hg) 7 ± 4 7 ± 4 11 ± 5*† <.001‡
Cardiac index (l/min/m2) 3.0 ± 0.6 3.3 ± 0.8 2.8 ± 0.8† .04‡
Pulmonary vascular resistance (WU) 2.5 ± 2.1 2.3 ± 1.9 3.0 ± 1.3 .40
Echocardiography
LV ejection fraction (%) 57 ± 5 58 ± 4 56 ± 5 .38
LV mass index (kg/m2) 93 ± 36 93 ± 23 98 ± 24 .79
LV E/e′ 12.9 ± 4.5 19.7 ± 11.7* 14.6 ± 7.2 .01‡
Septal wall e′ (cm/s) 6.5 ± 2.0 4.9 ± 1.4 8.0 ± 3.2*† .001‡
Lateral wall e′ (cm/s) 8.2 ± 2.9 7.5 ± 2.4 11.0 ± 4.2*† .001‡
Deceleration time (ms) 204 ± 51 222 ± 70 179 ± 53 .04‡
LA volume index (mL/m2) 40 ± 12 47 ± 20 57 ± 17* <.001‡
LA reservoir strain (%) 17.6 ± 7.2 13.0 ± 5.2 6.3 ± 2.5* <.001‡
RV dysfunction 9 (20%) 6 (43%) 20 (63%)* .001‡
≥ moderate tricuspid regurgitation 11 (24%) 5 (36%) 12 (38%) .43
Medication
Beta-blockers 37 (82%) 10 (71%) 27 (84%) .57
Sotalol 0 2 (14%) 1 (3%) .03‡
Calcium channel blocker 2 (4%) 1 (7%) 2 (6%) .90
Amiodarone 0 0 2 (6%) .15
Digitalis 1 (2%) 0 7 (22%)* .005‡
Loop diuretics 34 (76%) 10 (71%) 27 (84%) .53
Laboratory test
NT-proBNP (ng/L) 481 (277–955) 1265 (485–2335) 1656 (1090–2567)* .05
Data are reported as mean ± SD, median (interquartile range), and n (%). Subgroups: 1) no history of atrial fibrillation (ie, Never AF); 2) earlier atrial
fibrillation and in sinus rhythm during the assessment (ie, Earlier AF); and 3) atrial fibrillation during the assessment (ie, Current AF). AF, atrial fibrillation;
LA, left atrial; LV, left ventricular; NT-proBNP, N-terminal pro–B-type natriuretic peptide; RV, right ventricular.
*P < .05 vs Never AF group (with Bonferroni correction).
†P < .05 vs Prior AF group (with Bonferroni correction).
‡P < .05.
180 Journal of Cardiac Failure Vol. 24 No. 3 March 2018
Fig. 2. Association between atrial fibrillation (AF) and right ventricular (RV) function. FAC, fractional area change; FWLS, free wall lon-
gitudinal strain; RV S′ systolic annular tissue velocity of the lateral tricuspid annulus; RV Tei-index, right ventricular myocardial performance
index; SPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion. *P < .05 vs Never AF group (with Bonferroni
correction). ‡P < .05 vs Prior AF group (with Bonferroni correction). Error bars indicate SEM.
Table 2. Correlates of Right Ventricular Dysfunction
Variable
Univariable Model PAP-Adjusted Model*
OR (95% CI) P Value OR (95% CI) P Value
Male sex 3.09 (1.23–7.76) .02† 2.76 (1.07–7.11) .04†
Any diagnosis of AF vs Never AF 5.20 (2.04–13.2) .001† 4.70 (1.82–12.1) .001†
Earlier AF vs Never AF 3.00 (0.83–10.9) .09 3.11 (0.83–11.6) .09
AF rhythm vs sinus rhythm 4.89 (1.94–12.3) .001† 4.18 (1.62–10.8) .003†
Coronary artery disease 2.47 (0.78–7.86) .1 2.09 (0.84–5.16) .1
Pacemaker 3.85 (1.06–14.0) .04† 4.26 (1.15–15.8) .03†
Chronic obstructive pulmonary disease 2.62 (0.82–8.34) .1 2.11 (0.64–6.93) .2
LV ejection fraction 0.61 (0.39–0.94) .03† 0.60 (0.38–0.94) .03†
LV E/e′ 1.89 (1.16–3.08) .01† 1.72 (1.03–2.87) .04†
Mean right atrial pressure 2.13 (1.26–3.61) .005† 1.91 (1.07–3.43) .03†
RV end-diastolic pressure 1.87 (1.15–3.03) .01† 1.59 (0.91–2.77) .1
Mean pulmonary artery pressure 1.72 (1.04–2.83) .03†
Pulmonary vascular resistance 2.34 (1.28–4.29) .006† 2.65 (1.08–6.49) .03†
≥Moderate tricuspid regurgitation 2.00 (0.81–4.96) .1 1.73 (0.68–4.39) .3
RA reservoir strain 0.33 (0.17–0.63) .001† 0.35 (0.18–0.68) .002†
RA emptying fraction 0.35 (0.19–0.62) <.001† 0.37 (0.20–0.67) .001†
RA compliance 0.40 (0.19–0.85) .02† 0.41 (0.19–0.91) .03†
AF, atrial fibrillation; CI, confidence interval; LV, left ventricular; OR, odds ratio; RA, right atrial.
*Each parameter was adjusted for mean pulmonary artery pressure (PAP). Odds ratios for continuous variables represent an SD change.
†P < .05.
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Right Atrial Function in Atrial Fibrillation Versus Sinus
Rhythm
RA reservoir strain could be measured in 70 patients
(76.9%), RA volume and emptying fraction in 72 (80.0%),
and RA compliance in 56 (61.5%). As seen in Fig. 3, RA
emptying fraction (16.2% vs 28.5%; P < .001) and RA
reservoir strain (9.5% vs 24.3%; P < .001) were lower in
AF than in sinus rhythm. RA volume index (62.7 vs
32.2 mL/m2; P < .001) was higher in AF than in sinus
rhythm. For several RA parameters, there was a significant
difference observed across the 3 subgroups. RA volume
index increased across these subgroups (Fig. 3A), and RA
emptying fraction and RA reservoir strain significantly
decreased (Fig. 3B and C). Patients with earlier AF who
were currently in sinus rhythm had significant lower RA
emptying fraction than sinus rhythm patients without history
of AF (41% vs 60%; P = .002). Patients with any diagnosis
of AF had lower RA compliance than patients without any
history of AF (P < .001; Fig. 3D).
The logistic regression models for the association with
RA emptying fraction and reservoir strain below their
medians are depicted in Table 3. Median RA emptying
fraction was 42% (IQR 24 to 65%) and median reservoir
strain was 18% (IQR 9%–28%). Atrial fibrillation and RV
dysfunction were the strongest determinants of reduced RA
emptying fraction and RA reservoir strain. In the patients in
sinus rhythm, earlier AF was also significantly associated
with lower reservoir strain compared with patients without
any history of AF, even after adjustment for RVEDP
(Table 3).
Discussion
The present study demonstrates that in patients with HFpEF,
RV and RA function are more depressed in patients with AF
than in patients in sinus rhythm. This association was inde-
pendent from afterload. Moreover, patients in sinus rhythm
during the assessment but who had earlier AF also displayed
more RV and RAdysfunction than patients without any history
of AF. Furthermore, reduced RA function was strongly and
independently related to RV dysfunction in HFpEF.
The observation that RV dysfunction is more prevalent in
patients with HFpEF who are in AF seems robust, because RV
function was assessed with the use of multiple parameters and
all of them pointed in the same direction. The present study
therefore confirms and extends previous reports regarding the
association between AF and RV dysfunction in HFpEF.4–7,9 In
addition, the simultaneous availability of right heart catheter-
ization and echocardiography in the present study, including
RA functional parameters, as well as the identification of a 3rd
subgroup consisting of patients in sinus rhythm but with earlier
AF, are novel and add to the current data of right heart per-
formance in HFpEF-AF. BesidesAF, reduced LVEF, LVdiastolic
dysfunction, and pacing were also independently associated with
RV dysfunction, similarly to previous observations.4,5,9
Right Ventricular Function in Atrial Fibrillation Versus
Sinus Rhythm
In general, RV dysfunction in HFpEF is strongly related
to increased pulmonary pressures.17 In the present study,
Fig. 3. Association between atrial fibrillation (AF) and right atrial (RA) function. *P < .05 vs Never AF group (with Bonferroni correc-
tion). ‡P < .05 vs Prior AF group (with Bonferroni correction). Error bars indicate SEM.
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patients with AF had higher PCWP and PAP than patients in
sinus rhythm. Both AF and RV dysfunction may therefore
relate to worsening HFpEF with increasing LV filling pres-
sures, leading on the one hand to LA hypertension, stretch,
fibrosis, and subsequently AF,18 and on the other hand further
backward to pulmonary hypertension (PH) and RV dysfunc-
tion. However, the association between AF and RV dysfunction
was independent from RV afterload, which is in line with 2
previous studies.4,9 It was suggested that AF may directly con-
tribute to RV dysfunction via impaired longitudinal
performance, because it was demonstrated that cardioversion
from AF to sinus rhythm was associated with an improve-
ment of RV longitudinal contraction.19 This is supported by
our finding that patients who were in AF had lower RV sys-
tolic tissue velocities than patients without any history of AF.
However, the present observations of reduced RV function
in patients with AF may also be caused by uncertainties of
the measure itself in the setting of AF. For example, LVEF
is generally underestimated and mitral regurgitation often over-
estimated with AF.12 Furthermore, heart rate irregularity may
also negatively affect biventricular function in heart failure,20
and a similar phenomenon occurs with permanent pacing in
HFpEF.5,9
In contrast, RV dysfunction was also more prevalent in
HFpEF patients with an earlier diagnosis of AF while
currently in sinus rhythm compared with patients without
any history of AF. In addition, the patients with earlier AF
also displayed more RA remodeling than patients without a
history of AF. To our knowledge, these findings—in HFpEF
patients who were all in sinus rhythm—are novel and
suggest that also factors other than heart rhythm play a role
in the development of right-side remodeling in patients
with HFpEF and AF. For example, impaired RA function
and loss of “atrial kick” limits Frank-Starling recruitment,
which may further impair myocardial performance and
might explain the close relation between RA remodeling
and reduced RV function. Furthermore, the progression of
AF is often an indication of worsening HFpEF.21 We there-
fore hypothesize that these observations might also be an
expression of the development of right-side perturbations,
simultaneously with left-side remodeling in the course of
the disease, as similarly described by Borlaug et al recently
in another HFpEF cohort.22
Right Atrial Function in Atrial Fibrillation Versus Sinus
Rhythm
HFpEF patients with AF had higher RA volumes and lower
RA function and compliance. Interestingly, RA strain, emp-
tying fraction, and compliance were also lower in HFpEF
patients with earlier AF who were in sinus rhythm during the
assessment. There are several potential explanations for these
findings.
Although there are some distinct differences in anatomy
between both atria,23 AF and longstanding atrial dyssynchrony
and stress in the setting of AF leads to structural remodel-
ing changes in both atria simultaneously.24 Furthermore,
systemic inflammation and endothelial dysfunction driven by
predominant comorbidities with HFpEF, such as renal dys-
function, diabetes mellitus, and obesity, target both atria equally
and may facilitate atrial remodeling and AF.25 In patients with
paroxysmal AF, early signs of HFpEF with increased LA pres-
sures at rest or during exercise are already prevalent and
clinically relevant.26 The left atrium serves as a buffer between
the LV and pulmonary circulation, prohibiting transmission
of left-side filling pressures to the pulmonary circulation. LA
remodeling in HFpEF was therefore previously linked to in-
creased LA pressure and PVR and elevated RV afterload.10
Table 3. Correlates of Right Atrial Dysfunction
Variable
↓ RA Emptying Fraction ↓ RA Reservoir Strain
OR (95% CI) P Value OR (95% CI) P Value
Unadjusted model*
Any diagnosis of AF vs Never AF 17.33 (5.15–58.3) <.001‡ 14.50 (4.55–46.2) <.001‡
Earlier AF vs Never AF 3.86 (0.95–15.7) .06 4.46 (1.05–19.0) .04‡
LA volume index 2.94 (1.37–6.30) .006‡ 4.31 (1.75–10.64) .002‡
LA reservoir strain 0.20 (0.07–0.54) .002‡ 0.16 (0.05–0.53) .003‡
Mean right atrial pressure 3.75 (1.74–8.06) .001‡ 3.30 (1.60–6.79) .001‡
Mean pulmonary artery pressure 2.18 (1.20–3.99) .01‡ 1.91 (1.07–3.40) .03‡
Pulmonary vascular resistance 3.06 (1.37–6.85) .007‡ 1.57 (0.87–2.83) .1
RV end-diastolic pressure 1.75 (1.02–3.00) .04‡ 1.85 (1.07–3.20) .03‡
RV dysfunction 8.46 (2.78–25.8) <.001‡ 8.20 (2.68–24.9) <.001‡
≥Moderate tricuspid regurgitation 3.12 (1.07–8.99) .04‡ 1.30 (0.47–3.59) .6
RVEDP-adjusted model†
Any diagnosis of AF vs Never AF 13.28 (4.11–43.0) <.001‡ 16.35 (4.72–56.7) <.001‡
Earlier AF vs Never AF 3.86 (0.95–15.7) .06 4.57 (1.05–19.9) .04‡
LA volume index 2.94 (1.35–6.41) .006‡ 4.81 (1.77–13.1) .002‡
LA reservoir strain 0.21 (0.07–0.60) .003‡ 0.17 (0.05–0.58) .005‡
RV dysfunction 7.50 (2.42–23.2) <.001‡ 7.12 (2.29–22.2) .001‡
≥Moderate tricuspid regurgitation 3.18 (1.07–9.51) .04‡ 1.25 (0.44–3.57) .7
LA, left atrial; RV, right ventricular; other abbreviations as in Table 2.
*Only significant associations with RA dysfunction are depicted in the table.
†Each parameter was adjusted for RV end-diastolic pressure (RVEDP). Odds ratios for continuous variables represent an SD change.
‡P < .05.
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Thus, loss of compliance and buffering capacity of the LA
in HFpEF-AF might result in enhanced backward transmis-
sion of left-side pressures and may trigger RV and RA
remodeling.
In contrast, RA enlargement, stretch, and fibrosis in the
setting of HFpEF-PH may perhaps also contribute to an
RA-predominant substrate for AF, because we observed
that RV and RA atrial pressures were much higher in
patients with AF, compared with patients without AF diag-
nosis, than LVEDP and PCWP in AF versus no AF. In a
retrospective cohort of 239 patients with PH, primarily with
idiopathic pulmonary arterial hypertension and chronic throm-
boembolic PH, the prevalence of AF was 20% and the
presence of AF was associated with higher PVR and PAP.27
In another cohort, 58% of patients with PH due to left heart
failure had AF, but AF was also present in 23% of patients
with PH without left heart failure.28 The latter group of
patients also had more RA dilation and higher RA pressures
than PH patients without left heart failure and without AF.28
Furthermore, the onset of supraventricular tachyarrhythmias
in pulmonary arterial hypertension might be a sign of
further deterioration of right-side cardiac function.29 The
findings in the present study suggest that in some patients
with HFpEF with high pulmonary pressures, AF might be
triggered by RA overload rather than LA overload. Clearly,
the present study cannot comment further on this hypothe-
sis in the setting of HFpEF, owing to its cross-sectional
design, but perhaps in future studies—with continuous
monitoring of pulmonary pressures30—elevation of right-
side pressures can be linked to incident AF in patients with
HFpEF.
Study Limitations
This was a small observational cohort study that has
inevitable limitations. First, patients with earlier
echocardiography-suspected PH were referred for right heart
catheterization, resulting in a selection bias. Second, al-
though the duration of AF diagnosis was known, it was
unknown how long the patients with earlier AF were
currently in sinus rhythm. RA function may still be im-
paired in sinus rhythm but with a very recent conversion,
compared with patients who had much earlier conversion
from AF to sinus rhythm before the assessment. In addi-
tion, although the echocardiographic assessments were
performed with the use of multiple heart beats, AF can
cause uncertainty of the echocardiographic measurement
itself, owing to variation in cardiac filling and load with
irregular heart rate. However, this phenomenon is less
applicable to patients with a history of AF who were in
sinus rhythm during the assessment. Furthermore, the cross-
sectional design of the study prohibits any conclusions
regarding cause-effect relations between AF and RV dys-
function. Finally, because of the sample size, multivariable
associations with adjustment for more than 3 parameters
were not possible.
Conclusion
In patients with HFpEF, both RV and RA function were
gradually more depressed in patients who were in AF, as well
as in patients in sinus rhythm but who had earlier AF, than
in patients without any history of AF. These findings were
independent from pulmonary pressures and suggest simul-
taneous right-side remodeling in patients with HFpEF and AF.
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